Beroni Group Issues US$2 Million of Convertible Notes to Fund Research and Development Plans
28. Mai 2021 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, May 28, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise today...
Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export Permit
27. April 2021 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, April 27, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise...
Beroni Acquires Majority Interest in PENAO, an Anti-Cancer Drug Development Company
03. Februar 2021 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise today announces...
Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Received CE Certification
21. Dezember 2020 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the...
Beroni Group Launches a New Probiotics Health Product in China
10. November 2020 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise...
Beroni Group Named as a Top Infection Control Solutions Company in APAC for 2020
09. November 2020 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise...
Beroni Group Announces Successful Completion of SARS-CoV-2 Pseudovirus Neutralization Assay for Treatment of COVID-19
19. Oktober 2020 08:53 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise,...
Beroni Group Receives First Commercial Order for its COVID-19 Test Kits from Japan
08. September 2020 09:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an international diversified biopharmaceutical enterprise...
Beroni Group Signs Agreement with Genscript Biotech Corporation to Conduct Further Study to Develop Nanobody-based Medical Solution for COVID-19
12. August 2020 09:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), is pleased to announce that further to its announcement on August...
Beroni Group Has Successfully Constructed and Purified 24 Types of Nanobodies for Detection and Treatment of COVID-19
04. August 2020 09:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an international diversified biopharmaceutical enterprise focused...